New cancer drug combo enters first human tests

NCT ID NCT06532565

Recruiting now Disease control Sponsor: Gilead Sciences Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial is testing a new drug called GS-2121, taken as a tablet, alone or with an intravenous drug called zimberelimab, in 154 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see how the body handles the drug. It is a first-in-human study, so the focus is on safety and dosing, not yet on curing the cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GS-2121 (tablet) and zimberelimab (intravenous infusion)
What this could lead to: If successful, this could point toward a new treatment option for people with advanced solid tumors who have run out of standard therapies.
What could go wrong: This is a very early phase 1 trial with only 154 participants, so it is primarily testing safety and dosing. The drug may not shrink tumors or may cause significant side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMORS

Contacts and locations

Locations

Beth Israel Deaconess Medical Center
RECRUITING

Boston, Massachusetts, 02215, United States
NEXT Oncology
RECRUITING

San Antonio, Texas, 78229, United States
NEXT Virginia
RECRUITING

Fairfax, Virginia, 22031, United States
Princess Margaret Cancer Centre
RECRUITING

Toronto, M5G1Z5, Canada
Stanford Cancer Center
RECRUITING

Palo Alto, California, 94305, United States
The Ottawa Hospital Cancer Centre
RECRUITING

Ottawa, K1H 8L6, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.